RE:RE:RE:AACRThings may move faster than you think in phase 1b and phase 2. Eligble patients in the phase 1a will roll right into the phase 1b, giving that trial a head start with at least some patients. TH has also said as soon as they see signs of efficacy in phase 1b in one tumor type, they will take that to the FDA and get a phase 2 started in that ASAP. So, if things work out as we hope, we could have signs of efficacy in the phase 1b in some patients in June and a phase 2 started in that cancer type sometime int he summer. So, we hopefully will have one or more phase 2's running simultaneously with the phase 1b in the later half of 2022. We need signs of efficacy first for that however.
Biobob wrote:
Paul is NOT an entrepreneur, he's a big pharma big spending big budget guy he's not good at promoting his company. He his a rooky in finance and totally relies on his lame CFO for the financings and even worse IR now. I heard that that Gary Littlejohn is actually helping us in keeping the big spender in check. The science team is the best part of the company but is learning the ropes and taking longer than i should, 14 months for a MTD. Also more patients in P1b should mean longer timeline too.. they never say those things, do they.